Pharmaspur

Pharmaspur is a Tokyo-based clinical research organization (CRO) and biotechnology company that specializes in supporting venture drug discovery and clinical development in Japan. The company is the originator of GT-02037, a glycosylated somatostatin analog (G-SRIF) currently in Phase 2 clinical trials for the treatment of acromegaly. Pharmaspur provides a range of services including clinical trial management, regulatory affairs, and SEND data creation through its involvement in the Global SEND Alliance. The company has collaborated with major pharmaceutical firms such as Daiichi Sankyo, Eisai, and Takeda on various clinical programs spanning oncology, neurology, and metabolic diseases. Its expertise extends to various therapeutic modalities, including small molecules, peptides, and antisense oligonucleotides. Pharmaspur is recognized as a key player in the peptide-drug conjugate market due to its innovative work in glycosylated peptide therapeutics.